Acura Pharmaceuticals Inc. Expands Financing with Amended Loan Agreement, Secures Additional $100,000 from Abuse Deterrent Pharma, LLC

Reuters

06-24

Acura Pharmaceuticals Inc. Expands Financing with Amended Loan Agreement, Secures Additional $100,000 from Abuse Deterrent Pharma, LLC

Acura Pharmaceuticals Inc. has recently amended its existing financing agreement with Abuse Deterrent Pharma, LLC. The amended loan schedule, part of a secured promissory note initially dated November 10, 2022, outlines a series of additional loans granted to Acura Pharmaceuticals. The latest addition includes Loan #38, dated June 20, 2025, amounting to $100,000, which brings the total aggregated principal to $8,194,279. This series of loans, from the original note and subsequent additional loans, reflects Acura Pharmaceuticals' ongoing strategic financial maneuvers to support its operational and development activities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acura Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-061980), on June 24, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2545235140"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2545235140\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2545235140?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-24 22:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2545235140","market":"us","top_or_hot":-1,"title":"Acura Pharmaceuticals Inc. Expands Financing with Amended Loan Agreement, Secures Additional $100,000 from Abuse Deterrent Pharma, LLC","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Acura Pharmaceuticals Inc. Expands Financing with Amended Loan Agreement, Secures Additional $100,000 from Abuse Deterrent Pharma, LLC\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Acura Pharmaceuticals Inc. has recently amended its existing financing agreement with Abuse Deterrent Pharma, LLC. The amended loan schedule, part of a secured promissory note initially dated November 10, 2022, outlines a series of additional loans granted to Acura Pharmaceuticals. The latest addition includes Loan #38, dated June 20, 2025, amounting to $100,000, which brings the total aggregated principal to $8,194,279. This series of loans, from the original note and subsequent additional loans, reflects Acura Pharmaceuticals' ongoing strategic financial maneuvers to support its operational and development activities.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acura Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-061980), on June 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Acura Pharmaceuticals Inc. Expands Financing with Amended Loan Agreement, Secures Additional $100,000 from Abuse Deterrent Pharma, LLC</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAcura Pharmaceuticals Inc. Expands Financing with Amended Loan Agreement, Secures Additional $100,000 from Abuse Deterrent Pharma, LLC\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-24 22:19</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Acura Pharmaceuticals Inc. Expands Financing with Amended Loan Agreement, Secures Additional $100,000 from Abuse Deterrent Pharma, LLC\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Acura Pharmaceuticals Inc. has recently amended its existing financing agreement with Abuse Deterrent Pharma, LLC. The amended loan schedule, part of a secured promissory note initially dated November 10, 2022, outlines a series of additional loans granted to Acura Pharmaceuticals. The latest addition includes Loan #38, dated June 20, 2025, amounting to $100,000, which brings the total aggregated principal to $8,194,279. This series of loans, from the original note and subsequent additional loans, reflects Acura Pharmaceuticals' ongoing strategic financial maneuvers to support its operational and development activities.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acura Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-061980), on June 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250624:nNDL3qY1bl:1","article_id":"2545235140","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2545235140","pubTimestamp":1750774797,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Acura Pharmaceuticals Inc. Expands Financing with Amended Loan Agreement, Secures Additional $100,000 from Abuse Deterrent Pharma, LLC. Acura Pharmaceuticals Inc. has recently amended its existing financing agreement with Abuse Deterrent Pharma, LLC. The amended loan schedule, part of a secured promissory note initially dated November 10, 2022, outlines a series of additional loans granted to Acura Pharmaceuticals. The latest addition includes Loan #38, dated June 20, 2025, amounting to $100,000, which brings the total aggregated principal to $8,194,279. This series of loans, from the original note and subsequent additional loans, reflects Acura Pharmaceuticals' ongoing strategic financial maneuvers to support its operational and development activities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and sho","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","ACUR":"阿库拉制药"},"translate_title":"Acura Pharmaceuticals Inc.通过修订贷款协议扩大融资，从Abuse Deterrent Pharma，LLC获得额外100,000美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACUR":0.9},"content_text":"Acura Pharmaceuticals Inc. Expands Financing with Amended Loan Agreement, Secures Additional $100,000 from Abuse Deterrent Pharma, LLC\n    \n\n        Acura Pharmaceuticals Inc. has recently amended its existing financing agreement with Abuse Deterrent Pharma, LLC. The amended loan schedule, part of a secured promissory note initially dated November 10, 2022, outlines a series of additional loans granted to Acura Pharmaceuticals. The latest addition includes Loan #38, dated June 20, 2025, amounting to $100,000, which brings the total aggregated principal to $8,194,279. This series of loans, from the original note and subsequent additional loans, reflects Acura Pharmaceuticals' ongoing strategic financial maneuvers to support its operational and development activities.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acura Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-061980), on June 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}